Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
PR Newswire•21/10/2026•07:00 ET
0
Key Highlights
- ➤CALLIPER OLE retained favorable disability trends; 6.5% discontinued through January 27, 2026
- ➤CALLIPER showed 2.47x greater likelihood of 24-week confirmed disability improvement
- ➤Vidofludimus calcium reduced EBV-specific TCRβ matches by 0.65 versus placebo (p=0.0004)
- ➤GPC analysis found patients 1.5x more likely to achieve better disability outcomes versus placebo
- ➤ENSURE Phase 3 relapsing MS top-line results expected by year-end 2026
Expert Statements
Erik Lundgren, Chief Executive Officer of Immunic
“The data presented at MSToronto2026 provide complementary clinical and mechanistic evidence supporting the differentiated profile of vidofludimus calcium across the multiple sclerosis (MS) spectrum.”
Erik Lundgren, Chief Executive Officer of Immunic
“Importantly, the new CALLIPER open-label extension (OLE) analyses provide favorable long-term follow-up of the disability signals observed during the double-blind treatment period, while the Nurr1, Epstein-Barr virus (EBV), and disability endpoint analyses provide additional insight into the biology of disease progression and how treatment effects may be more comprehensively measured.”
Erik Lundgren, Chief Executive Officer of Immunic
“Together, these findings further support the clinical and scientific rationale for our planned Phase 3 program in progressive MS, which we expect to initiate later this year, while we also approach the top-line results from our fully enrolled Phase 3 ENSURE trials in relapsing MS, expected by year-end 2026.”
Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting PR Newswire
– New Phase 2 CALLIPER Open-Label Extension Data Support Durability of Disability Outcomes Observed During the Double-Blind Period With Continued Vidofludimus Calcium Treatment; Safety and Tolerability Profile Appeared Consistent With That Observed in the Double-Blind Period –
Get started
Create a free account to read the full story.